INmune Bio, Inc. (INMB)
- Previous Close
10.62 - Open
10.37 - Bid 10.08 x 200
- Ask 10.27 x 100
- Day's Range
9.66 - 10.55 - 52 Week Range
6.50 - 14.74 - Volume
178,611 - Avg. Volume
100,459 - Market Cap (intraday)
184.582M - Beta (5Y Monthly) 1.95
- PE Ratio (TTM)
-- - EPS (TTM)
-1.67 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.67
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
www.inmunebio.comRecent News: INMB
Performance Overview: INMB
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INMB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INMB
Valuation Measures
Market Cap
185.13M
Enterprise Value
159.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.18k
Price/Book (mrq)
4.85
Enterprise Value/Revenue
1.09k
Enterprise Value/EBITDA
-5.37
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.79%
Return on Equity (ttm)
-61.09%
Revenue (ttm)
155k
Net Income Avi to Common (ttm)
-30.01M
Diluted EPS (ttm)
-1.67
Balance Sheet and Cash Flow
Total Cash (mrq)
35.85M
Total Debt/Equity (mrq)
27.37%
Levered Free Cash Flow (ttm)
-1.4M